The 2020 program of IVHEM included key practical examples of innovative intervention studies, country elimination programs, and novel funding mechanisms for testing and treatment, all with a focus on meeting the 2030 elimination targets set by the World Health Organization (WHO).
Click here to download the full program: Program Book
You can find all accepted abstracts here: IVHEM 2020 Abstract Book
The Program of IVHEM 2020 can be viewed below.
Day 1 - Friday, 4 December 2020
Day 2 - Saturday, 5 December 2020
The International Viral Hepatitis Elimination Meeting (IVHEM) took place as a virtual meeting from 4-5 December 2020. IVHEM is a global forum for the exchange of practical experiences for translating diagnostic and therapy advances of viral hepatitis into broad applications that accelerate progress toward the elimination of viral hepatitis as a public health threat by 2030.
Hepatitis B and C affect more than 320 million people globally and can lead to liver disease and mortality from liver failure and hepatocellular carcinoma. More than 248 million people (3.8% of the world’s population) are chronically infected with HBV, and over 700,000 attributable deaths annually. An estimated 80 million people (globally, 1.1%) are chronically infected with hepatitis C virus (HCV), resulting in nearly 500,000 deaths annually.
Key issues to be addressed are how to translate research outcomes into public health policy and practice to meet the 2030 elimination targets. During this two day meeting, experts in viral hepatitis from around the globe will examine current evidence on how to implement programs that improve the prevention of viral hepatitis and increase the number of people accessing testing and treatment.
The 2020 program included practical examples of innovative intervention studies, country elimination programs, and novel funding mechanisms for testing and treatment.
We invite you to contribute to the elimination of viral hepatitis and look forward to welcoming you to the next edition of this unique meeting!
The Organizing Committee
General Information
Practical Information
The members of Scientific Committee (SC) advise the PC by providing them with suggestions for speakers and topics. In addition, members of the SC participate in reviewing submitted abstracts, and act as an ambassador of the meeting.
Maia Butsashvili, MD, MS, PhD - Health Research Union, Tblisi, Georgia
Jude Byrne - Australian Injecting & Illicit Drug Users League (AIVL), Australia
Vladimir Chulanov, MD, PhD, DSc - National Medical Research Center for TB and Infectious Diseases, Moscow, Russia
Andrea Cox, MD, PhD - Johns Hopkins School of Medicine, Baltimore, USA
Marko Korenjak, MA - European Liver Patients Association, Belgium
Khin Pyone Kyi - Myanmar Liver Foundation, Rangoon, Myanmar
Jeffrey Lazarus, PhD, MIH, MA - ISGlobal, Spain
Liudmyla Maistat - Medicines Patent Pool, Geneva, Switzerland
Shruti Mehta, PhD, MPH - Johns Hopkins School of Medicine, Baltimore, USA
Jean-Michel Pawlotsky, MD, PhD - Hôpital Henri Mondor, Paris, France
Homie Razavi, PhD, MBA - Center for Disease Analysis (CDA), Louisville, USA
Sonjelle Shilton, MPH - Foundation for Innovative New Diagnostics (FIND), Switzerland
Marcelo Silva, MD - Austral University Hospital, Buenos Aires, Argentina
